A new trial will test whether a set course of Brukinsa plus sonrotoclax, which target two pathways that drive hairy cell leukemia, can offer an alternative to chemotherapy.

In the phase 2 MASTERPLAN trial, adding SBRT to chemotherapy lowered the rate of cancer returning near the pancreas from 52.0% to 20.2% at one year.

Dr. Saum Ghodoussipour of Rutgers Cancer Institute answers top searched bladder cancer questions, from treatment and surgery side effects to sex and work.

Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient ...

Medicare will move ostomy supplies to six national contracts in 2028. Survivors and clinicians say a poor fit can lead to ...

For people with lung or pancreatic cancer driven by changes in the KRAS gene, research presented at the 2026 European Society ...

A Phoenix man with metastatic castration-sensitive prostate cancer shares how back pain led to a PSA test and how his family helped him cope. Prostate cancer grows slowly, and while 50% of men on ...

Five phase 3 trials presented at ESMO 2026 showed new options in small cell lung, bladder, prostate, KRAS G12C lung and ...

Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, ...

An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for ...

Four phase 3 trials at ESMO 2026 brought news for people with small cell, EGFR, MET and KRAS G12C lung cancer, plus a caution ...

Three phase 3 trials presented at the 2026 ESMO Congress looked closely at swallowing, daily functioning and blood counts in ...